Characterization of Optokinetic Nystagmus in Healthy Participants With a Novel Oculography Device.

Objective: To develop a proof-of-concept smart-phone-based eye-tracking algorithm to assess non-pathologic optokinetic (OKN) nystagmus in healthy participants. Current videonystagmography (VNG) is typically restricted to in-office use, and advances in portable vestibular diagnostics would yield immense public health benefits.

Study Design: Prospective cohort study.

Sexual selection matters in genetic rescue, but productivity benefits fade over time: a multi-generation experiment to inform conservation.

Globally, many species are threatened by population decline because of anthropogenic changes leading to population fragmentation, genetic isolation and inbreeding depression. Genetic rescue, the controlled introduction of genetic variation, is a method used to relieve such effects in small populations. However, without understanding how the characteristics of rescuers impact rescue attempts interventions run the risk of being sub-optimal, or even counterproductive.

AI-assisted exposure-response data analysis: Quantifying heterogeneous causal effects of exposures on survival times.

AI-assisted data analysis can help risk analysts better understand exposure-response relationships by making it relatively easy to apply advanced statistical and machine learning methods, check their assumptions, and interpret their results. This paper demonstrates the potential of large language models (LLMs), such as ChatGPT, to facilitate statistical analyses, including survival data analyses, for health risk assessments. Through AI-guided analyses using relatively recent and advanced methods such as Individual Conditional Expectation (ICE) plots using Random Survival Forests and Heterogeneous Treatment Effects (HTEs) estimated using Causal Survival Forests, population-level exposure-response functions can be disaggregated into individual-level exposure-response functions.

Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma.

Not available.

"If that would have lessened my symptoms, that would have been great...": a qualitative study about the acceptability of tecovirimat as treatment for mpox.

Background: Tecovirimat, an antiviral treatment for smallpox, was approved as a treatment for mpox by the European Medicines Agency in January 2022. Approval was granted under "exceptional circumstances" based on effectiveness found in pre-clinical challenge studies in animals and safety studies in humans showing minimal side effects. As clinical efficacy studies are still ongoing, there is currently limited information with regard to the acceptability of tecovirimat to treat mpox.